3 years ago
Jellagen Nets £8.7M Series A to Advance Jellyfish-Based Regenerative Medicine
Welsh biotech startup Jellagen has raised £8.7 million in a Series A funding round to further develop its jellyfish-derived collagen technology for regenerative medicine
The company's Collagen Type 0, extracted from jellyfish, offers a potentially safer and more versatile alternative to traditional mammalian collagen
The funding will support Jellagen's research partnerships and the development of its technology platform.
ProblemHealthcare
"Traditional collagen, commonly used in medicine for treating burns and wounds, comes from mammals and carries a higher risk of disease."
Solution
"Jellagen offers a purer and more versatile collagen derived from jellyfish, reducing the risk of disease associated with mammal-derived collagen."